- Home
- USIO vs PULM Comparison
USIO vs PULM Comparison
Compare USIO & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- PULM
- Stock Information
- Founded
- USIO 1998
- PULM 2003
- Country
- USIO United States
- PULM United States
- Employees
- USIO N/A
- PULM N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- PULM Health Care
- Exchange
- USIO Nasdaq
- PULM Nasdaq
- Market Cap
- USIO 36.6M
- PULM 30.9M
- IPO Year
- USIO N/A
- PULM N/A
- Fundamental
- Price
- USIO $1.56
- PULM $6.20
- Analyst Decision
- USIO Strong Buy
- PULM
- Analyst Count
- USIO 2
- PULM 0
- Target Price
- USIO $5.00
- PULM N/A
- AVG Volume (30 Days)
- USIO 50.2K
- PULM 8.4K
- Earning Date
- USIO 05-14-2025
- PULM 05-20-2025
- Dividend Yield
- USIO N/A
- PULM N/A
- EPS Growth
- USIO N/A
- PULM N/A
- EPS
- USIO 0.12
- PULM N/A
- Revenue
- USIO $82,931,840.00
- PULM $7,806,000.00
- Revenue This Year
- USIO $16.14
- PULM N/A
- Revenue Next Year
- USIO $13.51
- PULM $134.88
- P/E Ratio
- USIO $13.17
- PULM N/A
- Revenue Growth
- USIO N/A
- PULM 6.96
- 52 Week Low
- USIO $1.24
- PULM $1.72
- 52 Week High
- USIO $2.92
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- USIO 51.96
- PULM 46.38
- Support Level
- USIO $1.56
- PULM $5.88
- Resistance Level
- USIO $1.68
- PULM $6.85
- Average True Range (ATR)
- USIO 0.09
- PULM 0.30
- MACD
- USIO -0.01
- PULM 0.02
- Stochastic Oscillator
- USIO 47.83
- PULM 30.93
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.